Showing 80 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

PrEP programmes & uptake

US: Black Women Prefer HIV Prevention Shots, But Cost is a Factor

Editor's pick
POZ
22 April 2022
Injectable & long-acting PrEP

ViiV Healthcare is working with Medicines Patent Pool to progress voluntary licensing for cabotegravir long-acting for PrEP

Editor's pick
ViiV press release
4 April 2022
Injectable & long-acting PrEP

What is the use of anti-HIV injections when those who need it most can't use it?

Editor's pick
Bhekisisa
31 March 2022
Injectable & long-acting PrEP

No breakthrough HIV infections seen in women using injectable PrEP

News
25 March 2022
Injectable & long-acting PrEP

Community Response to ViiV’s Recent Statements on CAB-LA

Editor's pick
AfroCAB
18 March 2022
Injectable & long-acting PrEP

Unitaid to introduce new long-lasting injection to prevent HIV in Brazil and South Africa, as high-income countries begin deployment

Editor's pick
Unitaid
18 March 2022
Injectable & long-acting PrEP

MSF response: ViiV will not license new game-changing long-acting HIV prevention drug to generic manufacturers

Editor's pick
Médecins Sans Frontières
4 March 2022
Injectable & long-acting PrEP

ViiV Healthcare statement on voluntary license in enabling access to cabotegravir LA for PrEP in low- and middle-income countries

Editor's pick
ViiV Healthcare
4 March 2022
Injectable & long-acting PrEP

Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs

Editor's pick
AfroCAB
1 March 2022
Transmission & prevention

Top 5 stories on HIV prevention from CROI 2022

News
1 March 2022
Injectable & long-acting PrEP

Start planning HIV prevention injection rollout, South African experts say

Editor's pick
Spotlight
23 February 2022
Injectable & long-acting PrEP

Injected PrEP: breakthrough cases could have been detected sooner

News
22 February 2022
Injectable & long-acting PrEP

Injected PrEP: cabotegravir maintains its advantage over four years

News
17 February 2022
Injectable & long-acting PrEP

Members of Congress ask CDC to cut cost of new HIV prevention drug

Editor's pick
The Hill
14 February 2022
Injectable & long-acting PrEP

Injectable PrEP and COVID show we’re all in this together

News
7 January 2022
Injectable & long-acting PrEP

Fair Pricing Coalition Welcomes Approval Of Two-Month HIV Prevention Shot; Denounces ViiV Healthcare’s Exorbitant, Unsustainable Pricing

Editor's pick
Fair Pricing Coalition
26 December 2021
Injectable & long-acting HIV treatment

Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir

Editor's pick
FiercePharma
26 December 2021
Injectable & long-acting PrEP

GlaxoSmithKline's HIV prevention injectable Apretude threatens Gilead with FDA blessing. But will doctors use it?

Editor's pick
FiercePharma
26 December 2021
Injectable & long-acting PrEP

US approves injectable cabotegravir for PrEP

News
24 December 2021
Injectable & long-acting PrEP

AVAC Applauds US FDA Approval of the First injectable Form of HIV Pre-exposure Prophylaxis

Editor's pick
AVAC
21 December 2021
Injectable & long-acting PrEP

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention

Editor's pick
Food & Drug Administration
21 December 2021
New & experimental HIV treatments

Trials of long-acting islatravir for HIV treatment and prevention placed on hold

News
21 December 2021
Injectable & long-acting HIV treatment

Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

Editor's pick
Merck press release
14 December 2021
Injectable & long-acting HIV treatment

Long-Acting HIV Therapy Hits a Snag

Editor's pick
POZ
9 December 2021